Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD7 CAR-T for refractory/recurrent CD7-positive malignant hematologic tumors
ChiCTR2000038714Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD7 CAR-T cells (Shanghai General Hospital) in acute lymphoblastic leukemia (ALL), lymphoma, acute myeloid leukemia (AML) and 1 more, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Objective response rate (ORR, RRR) and Complete remission rate (CR). Planned start Oct 2020; status: not yet recruiting.
02
Drugs
anti-CD7 CAR-T cells (Shanghai General Hospital)
03
Conditions
acute lymphoblastic leukemia (ALL)lymphomaacute myeloid leukemia (AML)hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2000038714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038714.